gene therapy

MeiraGTx Announces Data from Phase 1/2 Clinical Trial of Gene Therapy for Patients with X-linked Retinitis Pigmentosa

MeiraGTx today announced topline data from the Phase 1/2 clinical trial MGT009 (NCT03252847) of botaretigenic sparoparvovec (formerly called AAV-RPGR), an investigational gene therapy in development for the treatment of patients with X-linked retinitis pigmentosa (XLRP) with disease-causing variants in the RPGR gene. Treatment with botaretigen sparoparvovec was found to be generally safe and well tolerated, …

MeiraGTx Announces Data from Phase 1/2 Clinical Trial of Gene Therapy for Patients with X-linked Retinitis Pigmentosa Read More »

$12 billion global gene therapy industry through 2031 –

Dublin, June 23, 2022 (GLOBE NEWSWIRE) — The “Global Gene Therapy Market Report 2022, Vector, Application, End Users” report has been added to ResearchAndMarkets.com’s offer. This report provides strategists, marketers, and senior management the crucial information they need to assess the global Gene Therapy market. This report focuses on the Gene Therapy Market which is …

$12 billion global gene therapy industry through 2031 – Read More »